Roni Nitecki1, Alexander Melamed2, Allison A Gockley2, Jessica Floyd3, Kate J Krause4, Robert L Coleman5, Ursula A Matulonis6, Sharon H Giordano7, Karen H Lu1, J Alejandro Rauh-Hain8. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 2. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America. 3. Department of Obstetrics and Gynecology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States of America. 4. Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 5. US Oncology Research, The Woodlands, TX, United States of America. 6. Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America. 7. Departments of Health Services Research and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 8. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: jarauh@mdanderson.org.
Abstract
BACKGROUND: Clinical trials demonstrated that PARPi (poly [adenosine diphosphate-ribose]-ADP polymerase inhibitor) therapy is effective in solid tumors. However, long term effects such as therapy-related myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) are poorly described. We sought to quantify whether PARPi therapy is associated with the development of MDS/AML. METHODS: Medline, Embase, and Cochrane databases were searched (inception to January 6, 2020) and phase 2 and 3 clinical trials that randomized patients with solid tumors to a PARPi or control therapy were included. The PRISMA guidelines were used to extract data independently by multiple authors. We extracted person-time and number of cases of MDS/AML in the PARPi and control arms of each study and pooled results with a random-effects Poisson regression model. The pooled incidence rate ratio (IRR) for MDS/AML among patients randomized to PARPi therapy was compared to those randomized to a control. RESULTS: We identified 14 studies that included 5739 patients. Accounting for intra-study clustering, the risk of MDS/AML was similar in patients who were randomly assigned to receive PARPi compared to controls (IRR 1.32, 95% confidence interval [CI] 0.78-2.26). In the front-line setting, PARPi therapy was associated with developing MDS/AML (IRR 5.43, 95% CI 1.51-19.60). Among patients treated for recurrence, however, the risk of MDS/AML appeared to be similar among patients randomized to PARPi or control treatment. Among studies that included only patients with a BRCA mutation, the risk of MDS/AML was similar in both treatment groups (IRR 0.83, 95% CI 0.45-1.53), but PARPi therapy was associated with MDS/AML in studies with an unrestricted population (IRR 2.43, 95% CI 1.17-5.06). CONCLUSION: The pooled overall effect was not statistically significant. However, treatment with PARPi was associated with a statistically significant increase in the incidence of MDS/AML among patients receiving front-line cancer therapy and those with limited prior exposure to chemotherapy.
BACKGROUND: Clinical trials demonstrated that PARPi (poly [adenosine diphosphate-ribose]-ADP polymerase inhibitor) therapy is effective in solid tumors. However, long term effects such as therapy-related myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) are poorly described. We sought to quantify whether PARPi therapy is associated with the development of MDS/AML. METHODS: Medline, Embase, and Cochrane databases were searched (inception to January 6, 2020) and phase 2 and 3 clinical trials that randomized patients with solid tumors to a PARPi or control therapy were included. The PRISMA guidelines were used to extract data independently by multiple authors. We extracted person-time and number of cases of MDS/AML in the PARPi and control arms of each study and pooled results with a random-effects Poisson regression model. The pooled incidence rate ratio (IRR) for MDS/AML among patients randomized to PARPi therapy was compared to those randomized to a control. RESULTS: We identified 14 studies that included 5739 patients. Accounting for intra-study clustering, the risk of MDS/AML was similar in patients who were randomly assigned to receive PARPi compared to controls (IRR 1.32, 95% confidence interval [CI] 0.78-2.26). In the front-line setting, PARPi therapy was associated with developing MDS/AML (IRR 5.43, 95% CI 1.51-19.60). Among patients treated for recurrence, however, the risk of MDS/AML appeared to be similar among patients randomized to PARPi or control treatment. Among studies that included only patients with a BRCA mutation, the risk of MDS/AML was similar in both treatment groups (IRR 0.83, 95% CI 0.45-1.53), but PARPi therapy was associated with MDS/AML in studies with an unrestricted population (IRR 2.43, 95% CI 1.17-5.06). CONCLUSION: The pooled overall effect was not statistically significant. However, treatment with PARPi was associated with a statistically significant increase in the incidence of MDS/AML among patients receiving front-line cancer therapy and those with limited prior exposure to chemotherapy.
Authors: Lindsay M Morton; Graça M Dores; Sara J Schonfeld; Martha S Linet; Byron S Sigel; Clara J K Lam; Margaret A Tucker; Rochelle E Curtis Journal: JAMA Oncol Date: 2019-03-01 Impact factor: 31.777
Authors: Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier Journal: Lancet Oncol Date: 2017-07-25 Impact factor: 41.316
Authors: Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley Journal: N Engl J Med Date: 2011-01-05 Impact factor: 91.245
Authors: Joyce O'Shaughnessy; Lee Schwartzberg; Michael A Danso; Kathy D Miller; Hope S Rugo; Marcus Neubauer; Nicholas Robert; Beth Hellerstedt; Mansoor Saleh; Paul Richards; Jennifer M Specht; Denise A Yardley; Robert W Carlson; Richard S Finn; Eric Charpentier; Ignacio Garcia-Ribas; Eric P Winer Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Lindsay M Morton; Graça M Dores; Margaret A Tucker; Clara J Kim; Kenan Onel; Ethel S Gilbert; Joseph F Fraumeni; Rochelle E Curtis Journal: Blood Date: 2013-02-14 Impact factor: 22.113
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis Journal: N Engl J Med Date: 2012-03-27 Impact factor: 91.245
Authors: M E Robson; N Tung; P Conte; S-A Im; E Senkus; B Xu; N Masuda; S Delaloge; W Li; A Armstrong; W Wu; C Goessl; S Runswick; S M Domchek Journal: Ann Oncol Date: 2019-04-01 Impact factor: 32.976
Authors: Simran Deep Kaur; Dinesh Kumar Chellappan; Alaa A Aljabali; Murtaza Tambuwala; Kamal Dua; Deepak N Kapoor Journal: Med Oncol Date: 2022-09-30 Impact factor: 3.738